New agents and mTOR inhibitors

Oncogenes and genetic aberration

HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

Diverse genetic alterations in triple-negative breast cancers after neoadjuvant chemotherapy

Young women with breast cancer more likely to respond to neoadjuvant chemotherapy

Chemo after complete surgical removal of local or regional breast cancer recurrence increases survival rates

Fewer, bigger doses of radiotherapy benefit cancer patients

Transcriptional regulation of endothelial cell differentiation

Novel molecular insights on vertebrate genome stability maintenance

Expanding international collaboration at IFOM

Stem cell generation of tumors and tissue physiology

Regulating the p53 pathway